INHALE-1: A 26-week Primary Treatment Phase, with 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza Versus Rapid-acting Insulin Analog Injections, Both in Combination with a Basal Insulin, in Pediatric Subjects with Type 1 or Type 2 Diabetes Mellitus
You are being asked to take part in this research study because you have type 1 or type 2 diabetes. Diabetes is a condition in which your body has trouble controlling your blood glucose (sugar) levels on its own. The goal of this study is to learn things that may help people with diabetes. Your study doctor will be talking with you about this study and this form. You can take as much time as you need to think about whether or not you want to be in this study. You can also take a copy of this form with you to discuss with friends, family, or other doctors to help you decide. Please read this document carefully. Do not agree to be in this study unless all of your questions have been answered. You do not have to be in this study. If you decide not to be in this study, you will not be treated differently as a person just because you didn’t want to be in this study. Also, your regular care will not be impacted.
This study is currently enrolling.